当前位置: 首页 >> 检索结果
1881. [Diffuse large B-cell lymphoma expressing surface immunoglobulin heavy chain (Ig alpha) and lacking light chains].
作者: Miki Ando.;Yasushi Isobe.;Makoto Sasaki.;Koichi Sugimoto.;Jun Ando.;Kazuo Oshimi.
来源: Rinsho Ketsueki. 2005年46卷7期492-5页
A 59-year-old woman with goiter complained of nausea, vomiting and weight loss in April 2000. She underwent an endoscopic examination and was admitted to our hospital because gastric biopsy specimens revealed that she had diffuse large B-cell lymphoma. A thyroid biopsy also detected the diffuse infiltration of lymphoma cells, which were positive for CD19, CD20, CD38 and HLA-DR. Although the cells expressed surface immunoglobulin a chain, they lacked expressions of the kappa and lambda light chains. Chromosomal analysis of the thyroid cells showed 47, XX, t(2 ; 3)(q31 ; q13), + 3, t(8 ; 22)(q24 ; q11). After five courses of biweekly CHOP chemotherapy, she received autologous peripheral blood stem cell transplantation in October 2000. Currently, she has maintained complete remission for more than 4 years.
1882. [Antiapoptotic functions of the retrovirally transferred API2-MALT1 gene].
t(11 ; 18)(q21 ; q21) is a specific chromosomal aberration in mucosa-associated lymphoid tissue (MALT) lymphoma, and produces chimeric transcript Apoptosis Inhibitor 2 (API2)-MALT1. Although it is known that API2 has an antiapoptotic effect, it is still unclear whether this also applies to API2-MALT1. To investigate its effects against various apoptotic stimuli, API2-MALT1 was expressed by means of retroviral infection on the epithelial cell line HeLa and the murine Pro-B cell line Ba/F3. On both these cell lines, API2-MALT1 was found to cause a significant reduction in UV-induced apoptosis. The apoptosis induced by doxorubicin was also inhibited by API2-MALT1, but not that induced by IL-3 withdrawal from Ba/F3. These findings suggest that API2-MALT1 has an antiapoptotic effect on both epithelial and lymphoid cells and that this effect depends on the apoptotic stimulus.
1883. [Tumor suppression by cellular senescence: molecular link between aging and cancer].1884. [Gene therapy for patients with malignant melanoma].
作者: Toshiaki Saida.;Kazuhiko Matsumoto.;Toshiro Kageshita.;Masaaki Mizuno.;Jun Yoshida.
来源: Nihon Rinsho. 2005年63 Suppl 12卷566-71页 1885. [Gene therapies for bladder cancer].1886. [Gene therapy for breast cancer].1887. [TSLC1/IGSF4, a potential target of suppression for the invasion and metastasis of human cancer].1888. [Genetic testing and gene-based testing for hematological disorder].1889. [Genetic testing and gene--based testing for colorectal cancer].
作者: Takashi Yabana.;Akira Goto.;Yoshiaki Arimura.;Yasuhisa Shinomura.;Kozo Imai.
来源: Nihon Rinsho. 2005年63 Suppl 12卷217-22页 1890. [Genetic testing and gene-based testing for familial tumor].1891. [Somatic mosaicism in genetic diseases].1892. [Cancer genomics in post-sequence era].1893. [Gene expression analysis of acute myeloid leukemia to understand leukemogenic pathways associated with differentiation inhibition].1894. [Gene expression profiling for prediction of response to chemotherapy].
Numerous genes whose expression is controlled by complex regulatory networks are involved in the development and progression of each cancer,and those genes will be the key factors for determining each characteristic of the tumor. The recent development of DNA microarray and related technologies provides an opportunity to perform more detailed characterization( profiling) of individual tumor cells. Indeed, the gene expression profile of a tumor provides a unique molecular portrait or signature that can be correlated with clinical behavior and drug responsiveness. The development of personalized( or customized) medicine and molecularly targeted drugs is enthusiastically awaited based on the results of research examining genomic diversity such as SNPs( single nucleotide polymorphisms), gene expression profiling with DNA microarrays, and analysis of protein expression and interactions.
1895. [Wnt-beta-catenin signaling in bone metabolism].
The Wnt-beta-catenin signaling pathway is involved in cell proliferation, differentiation and morphogenesis. Recently, mutations of the low-density lipoprotein receptor-related protein 5 (LRP5 ) gene, a receptor of this signaling, have been described to be associated with both osteoporosis-pseudoglioma syndrome and the high bone mass phenotype. It was found that the loss of function of the LRP5 in both human and mice yielded a decrease in bone formation, and an active mutation in this same gene resulted in a high bone mass trait. Moreover, several groups and we reported that single nucleotide polymorphisms in the LRP5 gene predicted the bone mass. This pathway also affects the pathogenesis of osteoarthritis and multiple myeloma. These findings indicate that Wnt-beta-catenin signaling pathway plays important roles in the skeletal biology.
1897. [Cancer stem cells in cancer cell lines].
作者: Takao Setoguchi.;Toru Kondo.;Tetsuya Taga.
来源: Tanpakushitsu Kakusan Koso. 2005年50卷15期1995-2000页 1898. [Cancer initiation as mini-evolution].1899. [H. pylori-negative gastric MALT lymphoma].1900. [Long-term outcome in patients with gastric MALT lymphoma after H. pylori eradication].
作者: Masahiro Tajika.;Tsuneya Nakamura.;Hiroki Kawai.;Yasushi Yatabe.;Shigeo Nakamura.
来源: Nihon Rinsho. 2005年63 Suppl 11卷516-9页 |